G M Crooks1, J K Sato. 1. Division of Hematology/Oncology, Childrens Hospital of Los Angeles, CA 90027, USA.
Abstract
PURPOSE: The activity of the drug combination ifosfamide and etoposide (VP16) in refractory and relapsed childhood acute lymphoblastic leukemia (ALL) was assessed in a phase II study. PATIENTS AND METHODS: Twenty children with ALL, all heavily pretreated and in bone marrow relapse, were entered on the study. Drugs were given i.v. each day for 5 days at the following doses: ifosfamide 1.8 g/m2/day, VP16 100 mg/m2/day, and MESNA 2,880 mg/m2/day (as a uroprotectant); cycles were repeated every 28 days. At study entry, eight patients were in first relapse (five of whom had failed intensive reinduction regimens), seven were in second relapse, and five were in third relapse. All patients had received cyclophosphamide in regimens before relapse. RESULTS: Eight patients (40%; 95% confidence interval 19-64%) achieved complete bone marrow remission with ifosfamide/VP16. Three patients subsequently relapsed in the bone marrow while on ifosfamide/VP16 therapy. Duration of remission ranged from 21 to 247 days. Treatment was generally well tolerated, with myelosuppression the most common toxicity; fever and neutropenia occurred in 18 of 31 evaluable cycles. CONCLUSION: The combination of ifosfamide/VP16 has significant activity in recurrent and refractory childhood ALL with tolerable toxicity.
PURPOSE: The activity of the drug combination ifosfamide and etoposide (VP16) in refractory and relapsed childhood acute lymphoblastic leukemia (ALL) was assessed in a phase II study. PATIENTS AND METHODS: Twenty children with ALL, all heavily pretreated and in bone marrow relapse, were entered on the study. Drugs were given i.v. each day for 5 days at the following doses: ifosfamide 1.8 g/m2/day, VP16 100 mg/m2/day, and MESNA 2,880 mg/m2/day (as a uroprotectant); cycles were repeated every 28 days. At study entry, eight patients were in first relapse (five of whom had failed intensive reinduction regimens), seven were in second relapse, and five were in third relapse. All patients had received cyclophosphamide in regimens before relapse. RESULTS: Eight patients (40%; 95% confidence interval 19-64%) achieved complete bone marrow remission with ifosfamide/VP16. Three patients subsequently relapsed in the bone marrow while on ifosfamide/VP16 therapy. Duration of remission ranged from 21 to 247 days. Treatment was generally well tolerated, with myelosuppression the most common toxicity; fever and neutropenia occurred in 18 of 31 evaluable cycles. CONCLUSION: The combination of ifosfamide/VP16 has significant activity in recurrent and refractory childhood ALL with tolerable toxicity.
Authors: K Nguyen; M Devidas; S-C Cheng; M La; E A Raetz; W L Carroll; N J Winick; S P Hunger; P S Gaynon; M L Loh Journal: Leukemia Date: 2008-09-25 Impact factor: 11.528
Authors: Elizabeth A Raetz; Mitchell S Cairo; Michael J Borowitz; Susan M Blaney; Mark D Krailo; Tarek A Leil; Joel M Reid; David M Goldenberg; William A Wegener; William L Carroll; Peter C Adamson Journal: J Clin Oncol Date: 2008-08-01 Impact factor: 44.544
Authors: Todd M Cooper; Bassem I Razzouk; Robert Gerbing; Todd A Alonzo; Kathleen Adlard; Elizabeth Raetz; Alan S Gamis; John Perentesis; James A Whitlock Journal: Pediatr Blood Cancer Date: 2013-01-17 Impact factor: 3.167
Authors: Richard H Ko; Lingyun Ji; Phillip Barnette; Bruce Bostrom; Raymond Hutchinson; Elizabeth Raetz; Nita L Seibel; Clare J Twist; Elena Eckroth; Richard Sposto; Paul S Gaynon; Mignon L Loh Journal: J Clin Oncol Date: 2009-10-19 Impact factor: 44.544
Authors: Elizabeth A Raetz; Michael J Borowitz; Meenakshi Devidas; Stephen B Linda; Stephen P Hunger; Naomi J Winick; Bruce M Camitta; Paul S Gaynon; William L Carroll Journal: J Clin Oncol Date: 2008-08-20 Impact factor: 44.544
Authors: Kirk R Schultz; W Paul Bowman; Alexander Aledo; William B Slayton; Harland Sather; Meenakshi Devidas; Chenguang Wang; Stella M Davies; Paul S Gaynon; Michael Trigg; Robert Rutledge; Laura Burden; Dean Jorstad; Andrew Carroll; Nyla A Heerema; Naomi Winick; Michael J Borowitz; Stephen P Hunger; William L Carroll; Bruce Camitta Journal: J Clin Oncol Date: 2009-10-05 Impact factor: 44.544
Authors: Michael J Burke; Wanda L Salzer; Meenakshi Devidas; Yunfeng Dai; Lia Gore; Joanne M Hilden; Eric Larsen; Karen R Rabin; Patrick A Zweidler-McKay; Michael J Borowitz; Brent Wood; Nyla A Heerema; Andrew J Carroll; Naomi Winick; William L Carroll; Elizabeth A Raetz; Mignon L Loh; Stephen P Hunger Journal: Haematologica Date: 2018-12-13 Impact factor: 9.941